Overview

This trial is active, not recruiting.

Condition alzheimer's disease
Treatment [11c]pib
Phase phase 1
Sponsor Dean F. Wong, MD, PhD
Start date September 2013
End date December 2016
Trial size 21 participants
Trial identifier NCT01826110, NA_00033154

Summary

The purpose of this study is to investigate the radiotracer [11C] PIB in participants with probably Alzheimer's Disease (AD) and healthy age-matched controls.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Intervention model single group assignment
Masking open label
Primary purpose basic science
Arm
(Experimental)
[11C]PIB
[11c]pib
Approximately 15 mCI [11C]PIB IV x1

Primary Outcomes

Measure
Distribution Volumes of 11C-PIB
time frame: Approximately 2 years

Eligibility Criteria

Male or female participants from 18 years up to 80 years old.

Inclusion Criteria: - Male or female subjects at least 18 years of age - Subjects who in the opinion of the investigator based on medical history and physical exam can tolerate the PET scan procedures Exclusion Criteria: - Have clinically significant hepatic, renal, pulmonary, metabolic, or endocrine disturbances - Have current clinically significant cardiovascular disease. - Have a history of drug or alcohol abuse within the last year, or prior prolonged history of abuse - Have a clinically significant infectious disease, including Acquired Immune Deficiency Syndrome (AIDS) or Human Immunodeficiency Virus (HIV) infection or previous positive test for hepatitis - Women of childbearing potential must not be pregnant (negative urine beta-hCG at the time of screening and negative urine beta-hCG on the day of imaging) or lactating at screening or at day of imaging - Have a history of relevant severe drug allergy or hypersensitivity (Relevant severe drug allergies should be determined by the PI, and any questions about a subject's eligibility can be directed to Avid. If a subject has a history of severe drug allergies, it may be dangerous for them to participate in a study with a novel compound - Have received an investigational medication within the last 30 days. Current clinically significant or unstable medical comorbidities, as indicated by history or physical exam - Have received a radiopharmaceutical for imaging or therapy within the past 7 days prior to the imaging session for this study - Body weight > 300 pounds - History of significant radiation exposure - Participants with pacemakers, implanted electronic hearing devices, aneurysm clips, shrapnel, unallowed prosthetic or other metallic device in their bodies - Pre-existing CNS disease (other than dementia), endocrine, or severe cardiovascular disease (MI, CABG, angioplasty)

Additional Information

Official title "[11C] PIB Comparison Study to [18F] AV-45 in Subjects With Alzheimer's Disease (AD) and Age Matched Healthy Controls"
Principal investigator Dean F Wong, MD, PhD
Description The objectives of the study are: 1. To perform PET scans with [11C]PIB to use for direct (i.e., same-subjects) comparison of [11C]PIB and [18F]AV-45 2. To establish the most effective and reliable PET imaging method to detect amyloid deposition in AD, in order to understand disease progression and subsequently evaluate treatment effects. 3. To ascertain a PET imaging method that will minimize discomfort for subjects, thus increasing the potential for clinical follow-up scans, by reducing the patient burden and potential cost of future PET examinations. A separate protocol/study will be conducted using [18F] AV-45. Participants who enroll in this protocol using [11C] PIB will be consented to participate in the [18F] AV-45 (IRB # NA_00033155) protocol/study as it is a mandatory requirement that participants participate in both protocols.Up to 20 participants with mild to moderate Alzheimer's Disease and 10 healthy volunteers will participate in this study.
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Johns Hopkins University.